PMID- 31438528
OWN - NLM
STAT- MEDLINE
DCOM- 20200305
LR  - 20240109
IS  - 1660-3397 (Electronic)
IS  - 1660-3397 (Linking)
VI  - 17
IP  - 9
DP  - 2019 Aug 21
TI  - Indole-4-carboxaldehyde Isolated from Seaweed, Sargassum thunbergii, Attenuates 
      Methylglyoxal-Induced Hepatic Inflammation.
LID - 10.3390/md17090486 [doi]
LID - 486
AB  - Glucose degradation is aberrantly increased in hyperglycemia, which causes 
      various harmful effects on the liver. Glyoxalase-1 (Glo-1) is a ubiquitous 
      cellular enzyme that participates in the detoxification of methylglyoxal (MGO), a 
      cytotoxic byproduct of glycolysis that induces protein modification (advanced 
      glycation end-products, AGEs) and inflammation. Here, we investigated the 
      anti-inflammatory effect of indole-4-carboxaldehyde (ST-I4C), which was isolated 
      from the edible seaweed Sargassum thunbergii, on MGO-induced inflammation in 
      HepG2 cells, a human hepatocyte cell line. ST-I4C attenuated the MGO-induced 
      expression of inflammatory-related genes, such as tumor necrosis factor (TNF)-alpha 
      and IFN-gamma by activating nuclear factor-kappa B (NF-kappaB) without toxicity in HepG2 
      cells. In addition, ST-I4C reduced the MGO-induced AGE formation and the 
      expression of the receptor for AGE (RAGE). Interestingly, both the mRNA and 
      protein expression levels of Glo-1 increased following ST-I4C treatment, and the 
      decrease in Glo-1 mRNA expression caused by MGO exposure was rescued by ST-I4C 
      pretreatment. These results suggest that ST-I4C shows anti-inflammatory activity 
      against MGO-induced inflammation in human hepatocytes by preventing an increase 
      in the pro-inflammatory gene expression and AGE formation. Therefore, it 
      represents a potential therapeutic agent for the prevention of hepatic steatosis.
FAU - Cha, Seon-Heui
AU  - Cha SH
AUID- ORCID: 0000-0002-5004-3223
AD  - Department of Marine Biomedical Sciences, Hanseo University, Chungcheongnam-do 
      31962, Korea.
FAU - Hwang, Yongha
AU  - Hwang Y
AD  - Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 21999, 
      Korea.
AD  - College of Pharmacy, Gachon University, Incheon 21999, Korea.
FAU - Heo, Soo-Jin
AU  - Heo SJ
AD  - Jeju International Marine Science Center for Research & Education, Korea 
      Institute of Ocean Science & Technology (KIOST), Jeju 63349, Korea.
FAU - Jun, Hee-Sook
AU  - Jun HS
AUID- ORCID: 0000-0002-1166-4932
AD  - Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 21999, 
      Korea. hsjun@gachon.ac.kr.
AD  - College of Pharmacy, Gachon University, Incheon 21999, Korea. hsjun@gachon.ac.kr.
AD  - Gachon Medical and Convergence Institute, Gachon Gil Medical Center, Incheon 
      21999, Korea. hsjun@gachon.ac.kr.
LA  - eng
GR  - HI14C1135/Ministry of Health and Welfare of Korea/
PT  - Journal Article
DEP - 20190821
PL  - Switzerland
TA  - Mar Drugs
JT  - Marine drugs
JID - 101213729
RN  - 0 (AGER protein, human)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Indoles)
RN  - 0 (NF-kappa B)
RN  - 0 (Receptor for Advanced Glycation End Products)
RN  - 722KLD7415 (Pyruvaldehyde)
RN  - EC 4.4.1.5 (GLO1 protein, human)
RN  - EC 4.4.1.5 (Lactoylglutathione Lyase)
SB  - IM
MH  - Anti-Inflammatory Agents/isolation & purification/*pharmacology/therapeutic use
MH  - Drug Evaluation, Preclinical
MH  - Glycation End Products, Advanced/metabolism
MH  - Glycolysis/drug effects
MH  - Hep G2 Cells
MH  - Humans
MH  - Indoles/isolation & purification/*pharmacology/therapeutic use
MH  - Lactoylglutathione Lyase/antagonists & inhibitors/metabolism
MH  - NF-kappa B/metabolism
MH  - Non-alcoholic Fatty Liver Disease/chemically induced/*prevention & control
MH  - Pyruvaldehyde/*toxicity
MH  - Receptor for Advanced Glycation End Products/metabolism
MH  - Sargassum/*chemistry
MH  - Seaweed/chemistry
MH  - Signal Transduction/drug effects
PMC - PMC6780312
OTO - NOTNLM
OT  - AGEs
OT  - Sargassum thunbergii
OT  - hepatic steatosis
OT  - metabolic disease
OT  - seaweed
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2019/08/24 06:00
MHDA- 2020/03/07 06:00
PMCR- 2019/09/01
CRDT- 2019/08/24 06:00
PHST- 2019/06/05 00:00 [received]
PHST- 2019/07/19 00:00 [revised]
PHST- 2019/08/16 00:00 [accepted]
PHST- 2019/08/24 06:00 [entrez]
PHST- 2019/08/24 06:00 [pubmed]
PHST- 2020/03/07 06:00 [medline]
PHST- 2019/09/01 00:00 [pmc-release]
AID - md17090486 [pii]
AID - marinedrugs-17-00486 [pii]
AID - 10.3390/md17090486 [doi]
PST - epublish
SO  - Mar Drugs. 2019 Aug 21;17(9):486. doi: 10.3390/md17090486.